[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112018008490A2 - compostos e conjugados de criptoficina, sua preparação e seu uso terapêutico - Google Patents

compostos e conjugados de criptoficina, sua preparação e seu uso terapêutico

Info

Publication number
BR112018008490A2
BR112018008490A2 BR112018008490-5A BR112018008490A BR112018008490A2 BR 112018008490 A2 BR112018008490 A2 BR 112018008490A2 BR 112018008490 A BR112018008490 A BR 112018008490A BR 112018008490 A2 BR112018008490 A2 BR 112018008490A2
Authority
BR
Brazil
Prior art keywords
conjugates
therapeutic use
preparation
cryptophycin
cryptophycin compounds
Prior art date
Application number
BR112018008490-5A
Other languages
English (en)
Other versions
BR112018008490B1 (pt
Inventor
Bigot Antony
Bouchard Hervé
Brun Marie-Priscille
Clerc François
Zhang Jidong
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112018008490A2 publication Critical patent/BR112018008490A2/pt
Publication of BR112018008490B1 publication Critical patent/BR112018008490B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se aos compostos de criptoficina de fórmula (i): (i) a invenção também refere-se às cargas úteis de criptoficina, aos conjugados de criptoficina, às composições contendo-os e ao seu uso terapêutico, especialmente como agentes anticâncer. a invenção também se refere ao processo para a preparação desses conjugados.
BR112018008490-5A 2015-11-05 2016-11-03 Compostos e conjugados de criptoficina, processos para a preparação dos mesmos, medicamento e composição farmacêutica BR112018008490B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306751.7 2015-11-05
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (en) 2015-11-05 2016-11-03 Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use

Publications (2)

Publication Number Publication Date
BR112018008490A2 true BR112018008490A2 (pt) 2019-02-12
BR112018008490B1 BR112018008490B1 (pt) 2023-07-18

Family

ID=

Also Published As

Publication number Publication date
TW201730164A (zh) 2017-09-01
SI3371179T1 (sl) 2019-11-29
MY189448A (en) 2022-02-14
LT3371179T (lt) 2019-11-11
ECSP18034035A (es) 2018-05-31
KR20180073678A (ko) 2018-07-02
ZA201802322B (en) 2019-01-30
TWI714661B (zh) 2021-01-01
CA3003085A1 (en) 2017-05-11
US20190382391A1 (en) 2019-12-19
AU2016347724A1 (en) 2018-05-10
WO2017076998A1 (en) 2017-05-11
US10941139B2 (en) 2021-03-09
PT3371179T (pt) 2019-11-18
MX2018005379A (es) 2018-09-05
JP6929292B2 (ja) 2021-09-01
PL3371179T3 (pl) 2020-02-28
CR20180256A (es) 2018-08-13
PH12018500852A1 (en) 2018-10-29
EA201890898A1 (ru) 2018-10-31
RS59498B1 (sr) 2019-12-31
IL259067A (en) 2018-06-28
UY36979A (es) 2017-06-30
EP3371179A1 (en) 2018-09-12
CN108349960B (zh) 2022-05-27
SG11201803181SA (en) 2018-05-30
MA43160B1 (fr) 2019-12-31
ES2755101T3 (es) 2020-04-21
CL2018001210A1 (es) 2018-08-17
EA035625B1 (ru) 2020-07-17
AU2016347724B2 (en) 2021-04-01
US20210163458A1 (en) 2021-06-03
DK3371179T3 (da) 2019-11-11
AR106604A1 (es) 2018-01-31
HK1256754B (zh) 2020-06-05
HRP20191729T1 (hr) 2019-12-13
CO2018004581A2 (es) 2018-07-19
TN2018000131A1 (en) 2019-10-04
CN108349960A (zh) 2018-07-31
IL259067B (en) 2021-07-29
JP2018535255A (ja) 2018-11-29
CY1122441T1 (el) 2021-01-27
PH12018500852B1 (en) 2018-10-29
EP3371179B1 (en) 2019-08-07
HUE046033T2 (hu) 2020-01-28
NZ741734A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
BR112017017396A2 (pt) derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112016028476A8 (pt) compostos, composição, uso de um composto e método para o combate dos fungos nocivos
BR112017027414A2 (pt) Derivados hidroxiéster, processo para prepará- los e composições farmacêuticas os contendo
EA201891861A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112018074972A2 (pt) derivados de adenosina para uso no tratamento de câncer
BR112017016311A2 (pt) derivados de 9h-pirrolo-dipiridina
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
EA201591451A1 (ru) Модуляторы flap
BR112017011980A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana.
BR112018075334A2 (pt) composto, composição farmacêutica, e, uso de um composto
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112017006085A2 (pt) compostos 1-alquil-6-oxo-1,6-di-hidropiridin-3-ila e uso como moduladores sgrm
BR112015014583B1 (pt) compostos, processo para a preparação de compostos, compostos intermediários, composição, usos de um composto de fórmula i e método para combater fungos nocivos
BR112015016194A2 (pt) compostos, composição, utilização de um composto, método para o combate dos fungos nocivos e semente revestida
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
PH12018500014A1 (en) Total synthesis of shishijimicin a and analogs thereof
GB2564185A (en) Process for the preparation of derivatives of benzodioxole

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2016, OBSERVADAS AS CONDICOES LEGAIS